Alira Health, a global healthcare consulting and research organization, today released its fifth annual report on the state of the contract development and manufacturing organization (CDMO) market in ...

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE ® natural killer (NK) ...

SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the ...

The development of Phenesafe AI is driven by PharmAla’s drug development philosophy: ...

Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT ...

Gross profit for the first quarter of 2025 increased by $440 thousand, or 4.0%, to $11.4 million, compared with a gross profit of $10.9 million for the same quarter of 2024, as a result of higher ...

Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development for intranasal delivery. By modulating ...

About VYKAT XR VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients. VYKAT XR is indicated for the treatment of ...

Fries brings over 15 years of leadership experience in senior living operations and asset management across both U.S. and international markets. Most recently, he served as EVP of U.S. Operations and ...

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses ...

CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC) Notably, ~92% of all evaluable patients have PD-L1 TPS <50%, including ...